<?xml version="1.0" encoding="UTF-8"?>
<p>Seventy-four patients initiated therapy. Sixty-seven patients received at least four cycles (90.5%) of treatment and 59 (80%) received all six planned cycles (
 <xref ref-type="fig" rid="f1-1040138">Figure 1</xref>). Of the planned 444 cycles, 406 (91.5%) were administered. Fifteen patients stopped therapy before receiving all six cycles (
 <xref ref-type="fig" rid="f1-1040138">Figure 1</xref>). After four cycles, the overall response rate was 86.5% (64/74) and the complete response rate (confirmed and unconfirmed complete responses) was 56.5% (42/74). At the end of treatment, the overall response rate was 84% (62/74) and the complete response rate was 75.5% (56/74). FDG-PET evaluations were performed after four cycles of treatment in 64 patients (100% of the 64 responders) and after cycle 6 in 59 patients (95% of the 62 responders). Interim and final FDG-PET were negative in 64% (41/64) and in 78% of evaluated patients (46/59), respectively.
</p>
